Unterehmen auf Watchlist setzen
DexCom
ISIN: US2521311074
WKN: A0D9T1
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

DexCom · ISIN: US2521311074 · PR Newswire (ID: 20240925DC15925)
25 September 2024 11:00PM

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit


NEW YORK, Sept. 25, 2024 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the "Class Period"), of the important October 21, 2024 lead plaintiff deadline.

So what: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 21, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Details of the case: According to the lawsuit, during the Class Period, on July 25, 2024, DexCom announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of DexCom's salesforce; notably, that it was not truly equipped to execute on DexCom's perceived growth potential. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.

      Phillip Kim, Esq.

      The Rosen Law Firm, P.A.

      275 Madison Avenue, 40th Floor

      New York, NY 10016

      Tel: (212) 686-1060

      Toll Free: (866) 767-3653

      Fax: (212) 202-3827

      case@rosenlegal.com

      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dxcm-investors-have-opportunity-to-lead-dexcom-inc-securities-fraud-lawsuit-302258965.html

SOURCE THE ROSEN LAW FIRM, P. A.

Visuelle Wertentwicklung / Kursverlauf · DexCom
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Kontakt:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942